Materials and methods for treatment of hereditary haemochromatosis
Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.
1. A method for editing the haemochromatosis (HFE) gene in a human cell by genome editing, the method comprising:
(i) introducing into the human cell a Cas9 deoxyribonucleic acid (DNA) endonuclease or mRNA encoding the CAS9 DNA endonuclease, to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs) within or near the HFE gene or within or near regulatory elements of the HFE gene that results in a permanent deletion, insertion or correction of one or more mutations within or near the HFE gene and results in the restoration of HFE protein activity; and
(ii) introducing into the cell one or more single-molecule guide ribonucleic acids (sgRNAs) comprising a spacer sequence selected from the group consisting of nucleic acid sequences in SEQ ID NOs: 3610; 973; 378; 1029; 3598; 3634; 1142; 388; 1121; 3678; 1137; 3531; 3654; 1045; 1096; 3558 and 3585.
2. The method of claim 1 , wherein the method further comprises: introducing into the human cell a polynucleotide donor template comprising at least a portion of the wild-type HFE gene, at least a portion of DNA sequences that encode wild-type regulatory elements of the HFE gene, or at least a portion of cDNA corresponding to the wild-type HFE gene.
3. The method of claim 1 , wherein the method further comprises:
introducing into the human cell a polynucleotide donor template comprising at least a portion of the wild-type HFE gene or regulatory elements of the HFE gene, and wherein the Cas9 DNA endonuclease effects one single-strand break (SSB) or double-strand break (DSB) at a locus within or near the HFE gene or within or near regulatory elements of the HFE gene, that facilitates the insertion of the at least a portion of the wild-type HFE gene or regulatory elements of the HFE gene into chromosomal DNA that results in a permanent insertion or correction of the HFE gene or regulatory elements of the HFE gene.
4. The method of claim 1 , wherein the method further comprises:
introducing into the human cell a polynucleotide donor template comprising at least a portion of the wild-type HFE gene or regulatory elements of the HFE gene, wherein the Cas9 DNA endonuclease effects a pair of single-strand breaks (SSBs) or double-strand breaks (DSBs), the first at a 5′ locus and the second at a 3′ locus, within or near the HFE gene or within or near the regulatory elements of the HFE gene, that facilitates the insertion of the at least a portion of the wild-type HFE gene or regulatory elements of the HFE gene into chromosomal DNA between the 5′ locus and the 3′ locus that results in a permanent insertion or correction of the HFE gene or regulatory elements of the HFE gene.
5. The method of 3 , wherein the Cas9 DNA endonuclease is pre-complexed with the one or more sgRNAs.
6. The method of claim 1 , wherein the method further comprises:
introducing into the human cell two of the one or more sgRNAs, and wherein the Cas9 DNA endonuclease effects a pair of double-strand breaks (DSBs), the first at a 5′ DSB locus and the second at a 3′ DSB locus, within or near the HFE gene or within or near regulatory elements of the HFE gene, that results in a permanent deletion of the chromosomal DNA between the 5′ DSB locus and the 3′ DSB locus, wherein the two sgRNAs are modified sgRNAs.
7. The method of claim 1 , wherein the Cas9 mRNA and the one or more sgRNAs are either formulated into separate lipid nanoparticles or into the same lipid nanoparticle, or wherein the Cas9 mRNA is formulated into a lipid nanoparticle and the one or more sgRNAs are introduced into the human cell by an adeno-associated virus (AAV), or wherein the Cas9 mRNA is formulated into a lipid nanoparticle and the one or more sgRNAs are introduced into the human cell by electroporation.
8. A single-molecule guide ribonucleic acid (sgRNA) for editing the haemochromatosis (HFE) gene in a cell from a patient with hereditary hemochromatosis (HHC), comprising a spacer sequence selected from the group consisting of the nucleic acids sequences set forth by SEQ ID NOs: 3610; 973; 378; 1029; 3598; 3634; 1142; 388; 1121; 3678; 1137; 3531; 3654; 1045; 1096; 3558 and 3585.
9. The method of claim 2 , wherein the Cas9 mRNA, the one or more sgRNAs, and the polynucleotide donor template are either each formulated into separate lipid nanoparticles or into the same lipid nanoparticle.
10. The method of claim 2 , wherein the Cas9 mRNA is formulated into a lipid nanoparticle and both the one or more sgRNAs and the polynucleotide donor template are introduced into the human cell by an adeno-associated virus (AAV).
11. The method of claim 2 , wherein the Cas9 mRNA is formulated into a lipid nanoparticle, the one or more sgRNAs are introduced into the human cell by electroporation, and the polynucleotide donor template is introduced into the human cell by an adeno-associated virus (AAV).
12. The method of claim 1 , wherein the human cell is selected from the group consisting of a liver cell, skin cell, pancreatic cell, heart cell, joint cell, and a cell from the testes.
13. The method of claim 1 , wherein the Cas9 DNA endonucleases is pre-complexed with the one or more sgRNAs.
14. The method of claim 2 , wherein the at least a portion of the wild-type HFE gene or the at least a portion of cDNA corresponding to the wild-type HFE gene is exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, intronic regions, or combinations thereof.
15. The method of claim 2 , wherein the polynucleotide donor template is either a single or double stranded polynucleotide.
16. The method of claim 6 , wherein the Cas9 DNA endonuclease is pre-complexed with the two sgRNAs.